PMID: 16614540Apr 15, 2006Paper

Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis

Clinical Neuropharmacology
C HofmannB Schurad

Abstract

The high incidence of fibrotic cardiac valvulopathies reported in association with the 8beta-ergoline dopamine (DA) agonist, pergolide, and also case reports for cabergoline and bromocriptine have made it necessary to review the theoretical basis and actual findings in the case of another DA agonist, the 8alpha-ergoline lisuride (used since the 1970s for migraine prophylaxis as well as since the 1980s for its prolactin-lowering and anti-Parkinson activity). We have reviewed the pharmacology of lisuride in relation to other DA agonists, and we have performed a throughout literature search as well as a search of our own and other adverse drug reaction databases for a possible relationship of lisuride with cardiac valvulopathy or for any reports of fibrosis in other locations. Our review of the pharmacology and the literature strongly suggests that drug-induced cardiac valvulopathies are always related to a stimulatory drug effect on trophic 5-HT(2B) receptors. As lisuride is devoid of such an effect, but on the contrary is an extremely potent 5-HT(2B) antagonist, an association of lisuride therapy with cardiac valvulopathies seems to be highly unlikely. In agreement with this hypothesis, not a single report of a cardiac valvulopa...Continue Reading

References

Oct 1, 1991·Annals of Neurology·M H BhattD B Calne
Jan 1, 1990·Movement Disorders : Official Journal of the Movement Disorder Society·M E RodriguezJ A Obeso
May 13, 1989·BMJ : British Medical Journal·A HerzogR Ziegler
Nov 23, 1974·British Medical Journal·D B CalneA Petrie
Jul 1, 1967·The American Journal of the Medical Sciences·J R Graham
Oct 1, 1984·European Journal of Drug Metabolism and Pharmacokinetics·M HümpelG Pommerenke
Jul 10, 1980·Nature·M SchachterR Dorow
May 1, 1996·The European Journal of Neuroscience·K SchmuckH Lubbert
Aug 17, 2002·Brain : a Journal of Neurology·Fabrizio StocchiC Warren Olanow
Oct 23, 2002·Cardiology in Review·Jacques SerratricePierre-Jean Weiller
Dec 14, 2002·Mayo Clinic Proceedings·Allison M PritchettRaul E Espinosa
Jun 5, 2003·Clinical Neuropharmacology·Thomas Müller, Jürgen Fritze
Aug 26, 2003·Mayo Clinic Proceedings·William L Lanier
Dec 17, 2003·Archives of Neurology·UNKNOWN Parkinson Study Group
Jun 16, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Olivier RascolJean-Louis Montastruc
Jun 16, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Judit HorvathAnthony E Lang
Jun 16, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Pinky AgarwalSteven J Frucht
Oct 30, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Reinhard HorowskiHeinz H Pertz
Mar 23, 2005·Circulation·Björn I GustafssonHelge Waldum
Mar 26, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·William Bara-JimenezThomas N Chase
May 3, 2005·European Journal of Pharmacology·Sven JähnichenHeinz H Pertz

❮ Previous
Next ❯

Citations

Mar 26, 2008·European Journal of Endocrinology·Magnus LöndahlPer Katzman
Sep 10, 2010·Neurologia i neurochirurgia polska·Andrzej Bogucki, Jarosław Sławek
Apr 27, 2011·The Journal of Experimental Medicine·Clara DeesJörg H W Distler
Mar 5, 2013·Journal of Neural Transmission·K Ray ChaudhuriKapil D Sethi
Dec 9, 2014·Expert Opinion on Therapeutic Targets·Kjell FuxeDasiel O Borroto-Escuela
Feb 7, 2015·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Takafumi Hasegawa
Dec 10, 2015·Expert Opinion on Drug Safety·Roberto CeravoloUbaldo Bonuccelli
Nov 11, 2008·Annals of the New York Academy of Sciences·Riccardo RuffoliFrancesco Fornai
Jun 15, 2007·Nature Clinical Practice. Neurology·W R Wayne Martin
Jun 10, 2009·Current Opinion in Endocrinology, Diabetes, and Obesity·Dianne Cheung, Anthony Heaney
Jul 22, 2010·The New England Journal of Medicine·Steven R SmithUNKNOWN Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group
Nov 17, 2009·Journal of Veterinary Internal Medicine·M A Oyama, R J Levy
Mar 8, 2008·Expert Opinion on Drug Safety·Ubaldo Bonuccelli, Roberto Ceravolo
Mar 1, 2009·Therapeutic Advances in Neurological Disorders·O K Sujith, Carol Lane
Dec 10, 2014·Expert Review of Clinical Pharmacology·Vaishali K PatadiaUNKNOWN EU-ADR consortium
Aug 22, 2018·Nature Structural & Molecular Biology·John D McCorvyBryan L Roth
May 5, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Susan H FoxJonathan M Brotchie
May 16, 2009·Journal of Neurology·Claudia TrenkwalderJuliane Winkelmann
Mar 26, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Kersi J Bharucha, Steve M Blevins
Jun 10, 2009·Expert Opinion on Drug Safety·Richard B Rothman, Michael H Baumann
Dec 11, 2013·CNS Drugs·Marina Senek, Dag Nyholm
Jun 10, 2015·Expert Opinion on Drug Discovery·Cornelis J Van der Schyf
Feb 26, 2019·Journal of Neural Transmission·R Horowski, P-A Löschmann
Jun 5, 2019·Drugs & Aging·Harsh V GuptaRajesh Pahwa
Apr 10, 2008·Naunyn-Schmiedeberg's Archives of Pharmacology·D T Beattie, J A M Smith
Jul 1, 2009·Future Medicinal Chemistry·Jacques HamonLaszlo Urban
Feb 20, 2014·Expert Opinion on Drug Safety·Santiago Perez-LloretOlivier Rascol
Jul 16, 2008·Naunyn-Schmiedeberg's Archives of Pharmacology·Suneet MehrotraAntoinette MaassenVanDenBrink
Mar 26, 2015·Arquivos de neuro-psiquiatria·Alan Christmann FröhlichWalter André dos Santos Moraes
Jan 15, 2021·Bioorganic & Medicinal Chemistry·Basavarajaiah Suliphuldevara MatadaNagesh Gunavanthrao Yernale
Jan 10, 2021·International Journal of Molecular Sciences·Katrin DenzingerMarcel Bermudez
May 25, 2021·Frontiers in Molecular Biosciences·Alessandra de FeliceVittorio Limongelli
Nov 10, 2018·Organic Letters·Zhen LiCarsten Bolm
Sep 22, 2015·Journal of Medicinal Chemistry·Peter I Dosa, Elizabeth Ambrose Amin
Nov 18, 2017·The Journal of Organic Chemistry·Elisabet SelvaDavid Guijarro
Dec 4, 2019·Journal of Medicinal Chemistry·Arun K Ghosh, Margherita Brindisi
Aug 3, 2010·Parkinsonism & Related Disorders·Raja Mehanna, Joseph Jankovic
Mar 29, 2011·Pharmacology & Therapeutics·Joshua D HutchesonW David Merryman
Sep 1, 2011·Progress in Neurobiology·Philippe HuotJonathan M Brotchie

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.